The effect of cilostazol on right heart function and pulmonary pressure

Cardiovascular Therapeutics

Volumn 31, Issue 6, 2013, Pages e88-e93

  Sahin, Muslum ^a   Alizade, Elnur ^a   Pala, Selcuk ^a   Alici, Gokhan ^a   Ozkan, Birol ^a   Akgun, Taylan ^a   Emiroglu, Yunus ^a   Demir, Serdar ^a   Yazicioglu, Mehmet V ^a   Turkmen, Mehmet M ^a  

^a Kosuyolu Higher Education Training and Research Hospital   (Turkey)

Author keywords

Cilostazol; Right ventricular function and pulmonary artery pressure; Strain

Indexed keywords

CILOSTAZOL; WARFARIN;

ACCELERATION; ADULT; ARTERY THROMBOSIS; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; FOLLOW UP; FRACTIONAL AREA CHANGE; HEART EJECTION FRACTION; HEART RATE; HEART RIGHT VENTRICLE FUNCTION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMAGING SOFTWARE; LUNG ARTERY PRESSURE; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SYSTOLIC BLOOD PRESSURE; TISSUE DOPPLER IMAGING; TRANSIENT ISCHEMIC ATTACK; TRICUSPID ANNULAR PLANE SYSTOLIC EXCURSION; TWO DIMENSIONAL ECHOCARDIOGRAPHY; ULTRASOUND SCANNER; VEIN THROMBOSIS;

CILOSTAZOL; RIGHT VENTRICULAR FUNCTION AND PULMONARY ARTERY PRESSURE; STRAIN;

AGED; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PHOSPHODIESTERASE 3 INHIBITORS; PULMONARY ARTERY; TETRAZOLES; VENTRICULAR FUNCTION, RIGHT;

EID: 84888314938     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12041     Document Type: Article

References (29)

1. Lee SH, Choi SH, Choi S, et al. Impact of chronotropic effect of cilostazol after acute myocardial infarction: insights from change in left ventricular volume and function. Circ J 2007;71:106-111.
2. Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (cilostazol: a study in long-term effects). J Vasc Surg 2008;47:330-336.
3. Tsuchikane E, Takeda Y, Nasu K, Awata N, Kobayashi T. Balloon angioplasty plus cilostazol administration versus primary stenting of small coronary artery disease: final results of COMPASS. Catheter Cardiovasc Interv 2004;63:44-51.
4. Takigawa T, Matsumaru Y, Hayakawa M, Nemoto S, Matsumura A. Cilostazol reduces restenosis after carotid artery stenting. J Vasc Surg 2010;51:51-56.
5. Wang S, Cone J, Fong M, Yoshitake M, Kambayashi Ji, Liu Y. Interplay between inhibition of adenosine uptake and phosphodiesterase type 3 on cardiac function by cilostazol, an agent to treat intermittent claudication. J Cardiovasc Pharmacol 2001;38:775-783.
6. Yoshikawa H, Suzuki M, Hashimoto G, Otsuka T, Sugi K. Impact of cilostazol on left ventricular geometry and function: assessment by tissue Doppler imaging and two-dimensional speckle-tracking echocardiography. Echocardiography 2011;28:431-437.
7. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the american society of echocardiography. J Am Soc Echocardiogr 2010;23:685-713.
8. Sciomer S, Magri D, Badagliacca R. Non-invasive assessment of pulmonary hypertension: Doppler echocardiography. Pulm Pharmacol Ther 2007;20:135-140.
9. Posteraro A, Salustri A, Trambaiolo P, Amici E, Gambelli G. Echocardiographic estimation of pulmonary pressures. J Cardiovasc Med 2006;7:545-554.
10. Zuo DM, Wang CH, Wang YH. Deformation of the left and right ventricular longitudinal myocardium in fetuses with umbilical cord around neck. Chin Med J 2012;125:1608-1613.
11. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006;58:488-520.
12. Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999;83:3C-12C.
13. Cone J, Wang S, Tandon N, et al. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J Cardiovasc Pharmacol 1999;34:497-504.
14. Liu Y, Shakur Y, Yoshitake M, Kambayashi Ji J. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev 2001;19:369-386.
15. Shakur Y, Fong M, Hensley J, et al. Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart. Cardiovasc Drugs Ther 2002;16:417-427.
16. Umazume T, Funabashi N, Inoue T, et al. Adverse effects of cilostazol on left ventricular function in a patient with a sigmoid shaped interventricular septum. Int J Cardiol 2013;165:551-555.
17. Chemla D, Castelain V, Hervé P, Lecarpentier Y, Brimioulle S. Haemodynamic evaluation of pulmonary hypertension. Eur Respir J 2002;205:1314-1331.
18. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:78-84.
19. Bradford KK, Deb B, Pearl RG. Combination therapy with inhaled nitric oxide and intravenous dobutamine during pulmonary hypertension in the rabbit. J Cardiovasc Pharmacol 2000;36:146-151.
20. Van Obbergh LJ, Charbonneau M, Blaise G. Combination of inhaled nitric oxide with IV nitroglycerin or with a prostacyclin analogue in the treatment of experimental pulmonary hypertension. Br J Anaesth 1996;77:227-231.
21. Lobato EB, Beaver T, Muehlschlegel J, Kirby DS, Klodell C, Sidi A. Treatment with phosphodiesterase inhibitors type III and V: milrinone and sildenafil is an effective combination during thromboxane-induced acute pulmonary hypertension. Br J Anaesth 2006;96:317-322.
22. Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 1985;35:1144-1149.
23. Corbin JD, Francis SH. Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 1999;274:13729-13732.
24. Ikeda U, Ikeda M, Kano S, Kanbe T, Shimada K. Effect of cilostazol, a cAMP phosphodiesterase inhibitor, on nitric oxide production by vascular smooth muscle cells. Euro J Pharmacol 1996;314:197-202.
25. Chang LT, Sun CK, Sheu JJ, et al. Cilostazol therapy attenuates monocrotaline-induced pulmonary arterial hypertension in rat model. Circ J 2008;72:825-831.
26. Opie LH. Mechanism of cardiac contraction and relaxation. In: Libby P, Bonow RO, Mann DL, Zipes DP, Braunwald E, editors. Braunwald's Heart Disease: a textbook of cardiovascular medicine, 8th edn. Philadelphia, PA: Saunders Elsevier, Inc, 2008;509-539.
27. Gamssari F, Mahmood H, Ho JS, et al. Rapid ventricular tachycardias associated with cilostazol use. Tex Heart Inst J 2002;29:140-142.
28. Opie LH, Gersh BJ. Acute inotropes and inotropic dilators. In: Opie LH, editor. Drugs for the heart, 5th edn. Philadelphia, PA: WB Saunders, 2001;154-186.
29. Approval of New Drug Application for Pletal (Cilostazol). Letter to Otsuka American Pharmaceutical, Inc., from Center for Drug Evaluation and Research, Food and Drug Administration, Department of Health & Human Services; Rockville, MD; January 15, 1999.